Prevention of Hypoglycemia Among Diabetes Patients Admitted to Internal Medicine Departments With Nutritional Care
NCT ID: NCT03802942
Last Updated: 2021-04-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
500 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-07-01
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective randomized study to evaluate the efficacy of nutritional intervention for the prevention of hypoglycemia among diabetes patients with low albumin level that are admitted to internal medicine units, regardless of the reason for admission. All patients suitable for participation in the study will be asked to participate and be randomized to the interventional arm or the control arm.
After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS.
For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding". Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented.
Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study.
The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no oral nutritional supplement (ONS) will be prescribed or dispensed.
Following discharge, a 30-day follow-up call will be made to ascertain whether the patient is alive, whether the patient was re-admitted or re-hospitalized, and the usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.
After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS.
For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding". Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented.
Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study.
The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no oral nutritional supplement (ONS) will be prescribed or dispensed.
Following discharge, a 30-day follow-up call will be made to ascertain whether the patient is alive, whether the patient was re-admitted or re-hospitalized, and the usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome
NCT00302874
Diabetes
Hyperglycemia
COMPLETED
NA
Hypoglycemia in Hospitalized Patients
NCT02228642
Diabetes
Hypoglycemia
COMPLETED
Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study
NCT00813475
Diabetes
UNKNOWN
NA
The Glycaemic Effects of Glucerna® in Critically Ill Patients.
NCT02594865
Disorder of Glucose Regulation
COMPLETED
NA
Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke
NCT02054429
Ischemic Stroke
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1.2 Definitions: A. Hypoglycemia: a blood glucose level of 70 mg/dL or lower, regardless of symptoms B. Hypoalbuminemia: Albumin level below 3.5 g/dL upon admission to the hospital C. Adequate nutritional consumption: the consumption of at least half of the oral nutritional supplements D. Target population: Diabetes patients admitted to internal medicine units that have baseline hypoalbuminemia upon admission.
This is a prospective randomized study to evaluate the efficacy of nutritional intervention for the prevention of hypoglycemia among diabetes patients with low albumin level that are admitted to internal medicine units, regardless of the reason for admission. All patients suitable for participation in the study will be asked to participate and be randomized to the interventional arm or the control arm.
After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS.
2.3 Study population: All adult patients admitted to internal medicine units of the Wolfson Medical Center that will participate in the study. The admission to the unit can be either from the ER or as a transfer from other departments in the hospital.
Inclusion and Exclusion criteria specified above.
Drop-out criteria A. Patients in need of mechanical nutritional support (same as above), as a complication of the hospitalization.
B. Patients that have a designated nutritional care program recommended by the unit's dietician that includes ONS. For clarification purposes, fortification of the meal plan by changing the food items (i.e. low sugar items, high fat/protein and or etc.) will not be considered a drop-out indication, as long as ONS are not part of the intervention.
C. Patients with undocumented albumin level for the first 72 hours of the hospitalization to the internal medicine unit.
D. Patients that were enrolled in the study but were transferred from the internal medicine department to a different unit of treatment during the hospitalization. For clarification purposes, transfer to interventional radiology, interventional cardiology or any other units for a specific procedure is not considered a dropout criteria, as long as the patient is back in the internal medicine unit within 24-48 hours of the procedure.
2.4 Interventional program Interventional arm A. For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding".
B. Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented.
C. Patients in the intervention arm that will be unwilling to consume the ONS will not drop out of the study, but rather the follow-up will continue as usual (ITT design). The ONS will be offered every day, twice a day, regardless of the answer and the amount consumed. For patients that decline, the reason for lack of consumption will be documented.
D. The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no ONS will be prescribed or dispensed.
Control arm A. Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis (i.e. malnutrition screen, blood tests etc.) will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study, as long as no additional ONS are prescribed as part of the treatment plan (criteria 2 of the drop-out criteria).
B. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no ONS will be prescribed or dispensed.
Post discharge, all patients
Following discharge, a 30-day follow-up call will be made to ascertain key points:
A. Whether the patient is alive B. Whether the patient was re-admitted or re-hospitalized C. Usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.
3.1 informed consent The study will seek the approval of the local Institutional Review Board (IRB) as an interventional study. All patients participating (either in the treatment or control arms) will sign an informed consent upon study inclusion.
3.2 Data recording For each patient, a paper case report form (CRF) will be produced. The patient data recorded in the CRFs will include the following information A. demorgaphic data A.1. Age, sex, marital status B. Reason for admission, one or more of the following (multiple selection) B.1. Infection (pneumonia/other) B.2. Acute coronary disease B.3. Acute cerebrovascular accident (CVA) (all types) C Patient co-morbidities - one or more of the following (multiple selection) C.1. Hypertension C.2. Hyperlipidemia C.3. Chronic renal failure C.4. Cerebrovascular disease C.5. Coronary artery disease C.6. Congestive heart failure C.7. Chronic obstructive pulmonary disease C.8. Dementia (all stages) D Nutritional assessment - all the following (mandatory for all patients) D.1. Subjective global assessment D.2. Height (or knee height for patients that cannot be measured) D.3. Weight (or mid arm circumference for patients that cannot be measured) E Admission laboratory values - all the following (mandatory for all patients) E.1. Hemoglobin level E.2. White blood cell count E.3. C-Reactive protein E.4. Albumin and pre-albumin E.5. HbA1c E.6. Creatinine E.7. Recording of all glucose measurements F Medication plan (mandatory for all patients) F.1. Lipid lowering drugs (any type any dose) - y/n F.2. Antibiotic treatment (any type any dose) - y/n: for clarification: any type of antibiotic treatment given orally or by injection (IM, IV, intra-articular etc.). Topical antibiotics (either ointment or solution) will not be recorded.
F.3. Gluco-corticoid treatment (any type any dose) - y/n: for clarification: any type of gluco-corticoid treatment given orally or by injection (IM, IV, intra-articular etc.). Topical steroid treatment (either ointment or solution) will not be recorded.
F.4. Glucose lowering medications F.4.1. Insulin treatment (any type any dose) - y/n F.4.2. Glucagon-like peptide-1/Dipeptidyl peptidase-4 inhibitors (GLP1/DPP4i) (any type any dose) - y/n F.4.3. Metformin (any type any dose) - y/n F.4.4. Other (any type any dose) - y/n G.1. Meal consumption according to nutrition day analysis - daily 3 meals per day G.2. Glucerna ONS consumption - 2 bottles dispensed. Each day an estimation of each H Prognostic criteria H.1. Length of hospital stay - post discharge H.2. In-hospital and/or 30 day mortality (if applicable) H.3. 30-day readmission (if applicable).
Follow-up call For prognostic criteria assessment, a phone call will be made 30 days after discharge to ascertain survival and need for hospitalization. Readmission will be any and all referrals to an emergency room. A distinction will be made if the referral to the ER was followed by an admission to the hospital. The reason for readmission or re-hospitalization will not be recorded. For clarification purposes an admission for an elective surgery or procedure (i.e. coronary angiogram), or an elective admission for continuing care will not be considered a readmission.
This is a prospective randomized study to evaluate the efficacy of nutritional intervention for the prevention of hypoglycemia among diabetes patients with low albumin level that are admitted to internal medicine units, regardless of the reason for admission. All patients suitable for participation in the study will be asked to participate and be randomized to the interventional arm or the control arm.
After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS.
2.3 Study population: All adult patients admitted to internal medicine units of the Wolfson Medical Center that will participate in the study. The admission to the unit can be either from the ER or as a transfer from other departments in the hospital.
Inclusion and Exclusion criteria specified above.
Drop-out criteria A. Patients in need of mechanical nutritional support (same as above), as a complication of the hospitalization.
B. Patients that have a designated nutritional care program recommended by the unit's dietician that includes ONS. For clarification purposes, fortification of the meal plan by changing the food items (i.e. low sugar items, high fat/protein and or etc.) will not be considered a drop-out indication, as long as ONS are not part of the intervention.
C. Patients with undocumented albumin level for the first 72 hours of the hospitalization to the internal medicine unit.
D. Patients that were enrolled in the study but were transferred from the internal medicine department to a different unit of treatment during the hospitalization. For clarification purposes, transfer to interventional radiology, interventional cardiology or any other units for a specific procedure is not considered a dropout criteria, as long as the patient is back in the internal medicine unit within 24-48 hours of the procedure.
2.4 Interventional program Interventional arm A. For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding".
B. Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented.
C. Patients in the intervention arm that will be unwilling to consume the ONS will not drop out of the study, but rather the follow-up will continue as usual (ITT design). The ONS will be offered every day, twice a day, regardless of the answer and the amount consumed. For patients that decline, the reason for lack of consumption will be documented.
D. The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no ONS will be prescribed or dispensed.
Control arm A. Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis (i.e. malnutrition screen, blood tests etc.) will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study, as long as no additional ONS are prescribed as part of the treatment plan (criteria 2 of the drop-out criteria).
B. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no ONS will be prescribed or dispensed.
Post discharge, all patients
Following discharge, a 30-day follow-up call will be made to ascertain key points:
A. Whether the patient is alive B. Whether the patient was re-admitted or re-hospitalized C. Usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.
3.1 informed consent The study will seek the approval of the local Institutional Review Board (IRB) as an interventional study. All patients participating (either in the treatment or control arms) will sign an informed consent upon study inclusion.
3.2 Data recording For each patient, a paper case report form (CRF) will be produced. The patient data recorded in the CRFs will include the following information A. demorgaphic data A.1. Age, sex, marital status B. Reason for admission, one or more of the following (multiple selection) B.1. Infection (pneumonia/other) B.2. Acute coronary disease B.3. Acute cerebrovascular accident (CVA) (all types) C Patient co-morbidities - one or more of the following (multiple selection) C.1. Hypertension C.2. Hyperlipidemia C.3. Chronic renal failure C.4. Cerebrovascular disease C.5. Coronary artery disease C.6. Congestive heart failure C.7. Chronic obstructive pulmonary disease C.8. Dementia (all stages) D Nutritional assessment - all the following (mandatory for all patients) D.1. Subjective global assessment D.2. Height (or knee height for patients that cannot be measured) D.3. Weight (or mid arm circumference for patients that cannot be measured) E Admission laboratory values - all the following (mandatory for all patients) E.1. Hemoglobin level E.2. White blood cell count E.3. C-Reactive protein E.4. Albumin and pre-albumin E.5. HbA1c E.6. Creatinine E.7. Recording of all glucose measurements F Medication plan (mandatory for all patients) F.1. Lipid lowering drugs (any type any dose) - y/n F.2. Antibiotic treatment (any type any dose) - y/n: for clarification: any type of antibiotic treatment given orally or by injection (IM, IV, intra-articular etc.). Topical antibiotics (either ointment or solution) will not be recorded.
F.3. Gluco-corticoid treatment (any type any dose) - y/n: for clarification: any type of gluco-corticoid treatment given orally or by injection (IM, IV, intra-articular etc.). Topical steroid treatment (either ointment or solution) will not be recorded.
F.4. Glucose lowering medications F.4.1. Insulin treatment (any type any dose) - y/n F.4.2. Glucagon-like peptide-1/Dipeptidyl peptidase-4 inhibitors (GLP1/DPP4i) (any type any dose) - y/n F.4.3. Metformin (any type any dose) - y/n F.4.4. Other (any type any dose) - y/n G.1. Meal consumption according to nutrition day analysis - daily 3 meals per day G.2. Glucerna ONS consumption - 2 bottles dispensed. Each day an estimation of each H Prognostic criteria H.1. Length of hospital stay - post discharge H.2. In-hospital and/or 30 day mortality (if applicable) H.3. 30-day readmission (if applicable).
Follow-up call For prognostic criteria assessment, a phone call will be made 30 days after discharge to ascertain survival and need for hospitalization. Readmission will be any and all referrals to an emergency room. A distinction will be made if the referral to the ER was followed by an admission to the hospital. The reason for readmission or re-hospitalization will not be recorded. For clarification purposes an admission for an elective surgery or procedure (i.e. coronary angiogram), or an elective admission for continuing care will not be considered a readmission.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypoglycemia
Malnutrition; Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomized open label
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glucerna
2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
Group Type
EXPERIMENTAL
Glucerna
Intervention Type
DIETARY_SUPPLEMENT
1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
Control
Regular meal plan supplied by the hospital
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucerna
1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* admission to internal medicine units \&
* Diabetes mellitus type 2 \&
* Admission serum-albumin level below 3.5 gr/dL.
* Diabetes mellitus type 2 \&
* Admission serum-albumin level below 3.5 gr/dL.
Exclusion Criteria
* nasogastric \[NG\] tube
* percutaneous endoscopic gastrostomy \[PEG\]
* feeding jejunostomy
* total parenteral nutrition \[TPN\]
* chemotherapy or immunotherapy for malignancy during the past 6 months
* Malignancy with life expectancy of less than 6 months
* percutaneous endoscopic gastrostomy \[PEG\]
* feeding jejunostomy
* total parenteral nutrition \[TPN\]
* chemotherapy or immunotherapy for malignancy during the past 6 months
* Malignancy with life expectancy of less than 6 months
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Nutrition
INDUSTRY
Sponsor Role
collaborator
Eyal Leibovitz
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eyal Leibovitz
Chair, Internal medicine unit B, Laniado hospital
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eyal Leibovitz, MD
Role: PRINCIPAL_INVESTIGATOR
Yoseftal Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yoseftal hospital
Eilat, , Israel
Site Status
RECRUITING
Wolfson Medical Center
Holon, , Israel
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Israel
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EL001MENU-DM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
NCT02146404
COMPLETED
NA
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)
NCT00220987
COMPLETED
PHASE4
Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients
NCT03510078
RECRUITING
NA
Achieving Normal Glucose In Hospital Settings
NCT01359241
COMPLETED
NA
Identification of Inpatients at Risk for Poor Glycemic Control
NCT01043042
COMPLETED
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
NCT01283126
COMPLETED
NA
The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia
NCT02308293
COMPLETED
NA
Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes
NCT02866435
COMPLETED
EARLY_PHASE1
Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise
NCT03845114
COMPLETED
NA
Tight Glycemic Control and Insulin Administration During Parenteral Nutrition
NCT02035943
COMPLETED
NA
Hypoglycemia: Physician and Patient Perspectives
NCT01176656
COMPLETED
The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia
NCT03286816
COMPLETED
NA
Hypoglycemia and the Mineralocorticoid Receptor
NCT01394627
COMPLETED
NA
Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia
NCT03214107
COMPLETED
NA
Hyperglycemia in Patients with Stroke and Indication of Enteral Nutrition
NCT03422900
COMPLETED
NA
Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients
NCT03003507
COMPLETED
PHASE4
Hypoglycemia (Low Blood Sugar) and the Heart
NCT01980914
COMPLETED
NA
Liver Glycogen and Hypoglycemia in Humans
NCT03241706
ACTIVE_NOT_RECRUITING
PHASE1
Preventing Hypoglycemia
NCT01923688
COMPLETED
NA
Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.
NCT01627509
UNKNOWN
Hypoglycemia and Autonomic Nervous System Function-B
NCT03429946
COMPLETED
PHASE4
Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM
NCT00515801
COMPLETED
PHASE2/PHASE3
Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
NCT06746714
COMPLETED
NA
Treatment of Hypoglycemia in Type 1 Diabetes
NCT03489967
COMPLETED
NA